Anavex Life Sciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Anavex Life Sciences

AVXL 3.685

-3.7%

Dec 2 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ImGettingBetter	5/20/2022 11:35:04 AM
	of 120

Buy Rating Reaffirmed By H.C. Wainwright Buy on Anavex Life Sciences (AVXL) - $42.00 May 20 2022 - 06:25AM TipRanks H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report) today and set a price target of $42.00. The company's shares closed last Thursday at $9.27, close to its 52-week low of $7.13. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -45.5% and a 8.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Inovio Pharmaceuticals, and Aquestive Therapeutics. Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $39.00, implying a 348.8% upside from current levels. tipranks.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next